TSUBAKI was a Phase 2, randomized, multicenter, double-blind, placebo-controlled study of bardoxolone methyl in patients with type 2 diabetes and stage 3-4 chronic kidney disease. The primary efficacy endpoint was change from baseline in GFR measured by inulin clearance at week 16.
Disclaimer
Bardoxolone methyl is an investigational drug. Safety and efficacy have not been established by any regulatory agency.